Drug updated on 12/11/2024
| Dosage Form | Injection (intravenous; 150 mg/6 mL[25 mg/mL]) |
| Drug Class | CD20-directed cytolytic antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- Annualized Relapse Rate (ARR): The three most effective treatments for reducing ARR in relapsing multiple sclerosis were alemtuzumab, ofatumumab, and ublituximab. 3. 3-month Confirmed Disability Progression (3mCDP): Alemtuzumab, ocrelizumab, and ofatumumab were the top three treatments for delaying 3mCDP. 4. 6-month Confirmed Disability Progression (6mCDP): The most effective treatments were alemtuzumab, natalizumab, and either ocrelizumab or ofatumumab, depending on the definition used.
- There is no safety information available in the reviewed documents.
- There is no population types or subgroups information available in the reviewed documents.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Briumvi (ublituximab-xiiy) Prescribing Information. | 2022 | TG Therapeutics, Inc., Morrisville, NC |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis | 2023 | Journal of Comparative Effectiveness Research |